Skip to content

Study · Systematic review · 2020

13 results

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map.

Zhu J, Yu X, Zheng Y, Li J, Wang Y, Lin Y, He Z, Zhao W, Chen C, Qiu K, Wu J

The lancet. Diabetes & endocrinology29 Jan 2020Cited by 114 (Europe PMC)

PMID32006518 (opens in a new tab)DOI10.1016/s2213-8587(19)30422-x (opens in a new tab)PepBankPUB-32006518
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In people with diabetes, a meta-analysis estimate for liraglutide showed a lower relative risk of major adverse cardiovascular events.

    In plain wordsIn people with diabetes, liraglutide was linked to a lower risk of major heart and blood vessel events such as heart attack or stroke.

    Peptide
    Liraglutide
    Outcome
    DecreaseMajor adverse cardiovascular events
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    liraglutide (major adverse cardiovascular events [0·86; 0·77-0·96]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.
  2. 02HumanSystematic reviewEfficacy outcome

    In people with diabetes, a meta-analysis estimate for semaglutide showed a lower relative risk of major adverse cardiovascular events.

    In plain wordsIn people with diabetes, semaglutide was linked to a lower risk of major heart and blood vessel events such as heart attack or stroke.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse cardiovascular events
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide (major adverse cardiovascular events [0·76; 0·62-0·92]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.
  3. 03HumanSystematic reviewEfficacy outcome

    In people with diabetes, a meta-analysis estimate for semaglutide showed a lower relative risk of stroke; the upper confidence limit reached 1.00.

    In plain wordsIn people with diabetes, semaglutide was linked to a lower risk of stroke, but the result was borderline.

    Peptide
    Semaglutide
    Outcome
    DecreaseStroke
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide (major adverse cardiovascular events [0·76; 0·62-0·92] and stroke [0·67; 0·45-1·00]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of major adverse cardiovascular events.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to fewer major heart and blood vessel events. This is not a liraglutide-only result.

    Peptide
    Liraglutide
    Outcome
    DecreaseMajor adverse cardiovascular events (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of major adverse cardiovascular events.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to fewer major heart and blood vessel events. This is not a semaglutide-only result.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse cardiovascular events (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of death from cardiovascular disease.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to fewer deaths from heart and vessel disease. Not a liraglutide-only result.

    Peptide
    Liraglutide
    Outcome
    DecreaseCardiovascular death (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92], death from cardiovascular disease [0·87; 0·81-0·94]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of death from cardiovascular disease.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to fewer deaths from heart and vessel disease. Not a semaglutide-only result.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular death (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92], death from cardiovascular disease [0·87; 0·81-0·94]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of myocardial infarction.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to fewer heart attacks. This is not a liraglutide-only result.

    Peptide
    Liraglutide
    Outcome
    DecreaseMyocardial infarction (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92], death from cardiovascular disease [0·87; 0·81-0·94], myocardial infarction [0·92; 0·86-0·99]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of myocardial infarction.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to fewer heart attacks. This is not a semaglutide-only result.

    Peptide
    Semaglutide
    Outcome
    DecreaseMyocardial infarction (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92], death from cardiovascular disease [0·87; 0·81-0·94], myocardial infarction [0·92; 0·86-0·99]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of stroke.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to fewer strokes. This is not a liraglutide-only result.

    Peptide
    Liraglutide
    Outcome
    DecreaseStroke (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92], death from cardiovascular disease [0·87; 0·81-0·94], myocardial infarction [0·92; 0·86-0·99], stroke [0·84; 0·77-0·93]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of stroke.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to fewer strokes. This is not a semaglutide-only result.

    Peptide
    Semaglutide
    Outcome
    DecreaseStroke (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92], death from cardiovascular disease [0·87; 0·81-0·94], myocardial infarction [0·92; 0·86-0·99], stroke [0·84; 0·77-0·93]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 12HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of heart failure.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to less heart failure. This is not a liraglutide-only result.

    Peptide
    Liraglutide
    Outcome
    DecreaseHeart failure (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92], death from cardiovascular disease [0·87; 0·81-0·94], myocardial infarction [0·92; 0·86-0·99], stroke [0·84; 0·77-0·93], and heart failure [0·90; 0·83-0·99]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 13HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with diabetes, GLP-1 receptor agonists as a class were associated with a lower relative risk of heart failure.

    In plain wordsIn people with diabetes, GLP-1 drugs as a group were linked to less heart failure. This is not a semaglutide-only result.

    Peptide
    Semaglutide
    Outcome
    DecreaseHeart failure (GLP-1 receptor agonist class)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular events [RR 0·88; 95% CI 0·84-0·92], death from cardiovascular disease [0·87; 0·81-0·94], myocardial infarction [0·92; 0·86-0·99], stroke [0·84; 0·77-0·93], and heart failure [0·90; 0·83-0·99]
    1 context sentence
    Summary · context
    For this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.